An antihyperkinetic action by the serotonin la-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice

Journal of Pharmacological Sciences

Volumn 109, Issue 3, 2009, Pages 396-402

  Tsuchida, Rie ^a   Kubo, Masahiro ^a   Kuroda, Mariko ^a   Shibasaki, Yasuhiro ^a   Shintani, Norihito ^a   Abe, Michikazu ^b   Koves, Katalin ^c   Hashimoto, Hitoshi ^a,d   Baba, Akemichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder (ADHD) medication; Locomotor activity; Psychostimulant; Serotonin 5 HT1A receptor

Indexed keywords

AMPHETAMINE; ATOMOXETINE; FLUVOXAMINE; METHAMPHETAMINE; METHYLPHENIDATE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OSEMOZOTAN; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HYPERACTIVITY; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIOXANES; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYPERKINESIS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED ICR; PIPERAZINES; PROPYLAMINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 67249163770     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08297FP     Document Type: Article

References (22)

1. Solanto MV. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res. 2002;130:65-71.
2. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyper- activity disorder across the lifespan. Annu Rev Med. 2002;53: 113-131. (Pubitemid 34177874)
3. Andersen SL. Stimulants and the developing brain. Trends Pharmacol Sci. 2005;26:237-243.
4. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397-401. (Pubitemid 129501103)
5. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000;52:269-324.
6. Hashimoto H, Shintani N, Tanaka K, Mori W, Hirose M, Matsuda T, et al. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA. 2001;98:13355-13360. (Pubitemid 33051367)
7. Tanaka K, Shintani N, Hashimoto H, Kawagishi N, Ago Y, Matsuda T, et al. Psychostimulant-induced attenuation of hyper- activity and prepulse inhibition deficits in Adcyap1-deficient mice. J Neurosci. 2006;26:5091-5097. (Pubitemid 44315290)
8. Tomimoto S, Ojika T, Shintani N, Hashimoto H, Hamagami K, Ikeda K, et al. Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. J Pharmacol Sci. 2008;107:41-48.
9. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002; 159:1896-1901. (Pubitemid 35283256)
10. Matsuda T, Yoshikawa T, Suzuki M, Asano S, Somboonthum P, Takuma K, et al. Novel benzodioxan derivative, 5-(3-[((2S)-1,4- benzodioxan-2-ylmethyl)amino] propoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotoniniA receptors. Jpn J Pharmacol. 1995;69:357-366.
11. Abe M, Tabata R, Saito K, Matsuda T, Baba A, Egawa M. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3- benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. J Pharmacol Exp Ther. 1996;278:898-905.
12. Hjorth S, Westlin D, Bengtsson HJ. WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuro- pharmacology. 1997;36:461-465.
13. Serres F, Muma NA, Raap DK, Garcia F, Battaglia G, Van de Kar LD. Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypo- thalamus. J Pharmacol Exp Ther. 2000;294:296-301. (Pubitemid 30434700)
14. Ago Y, Koyama Y, Baba A, Matsuda T. Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology. 2003;45:1050-1056. (Pubitemid 37412250)
15. Fone KC, Nutt DJ. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol. 2005;5:87-93. (Pubitemid 40124540)
16. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6:6.
17. Przegalinski E, Filip M. Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol. 1997;8:699-706. (Pubitemid 28040001)
18. Przegalinski E, Siwanowicz J, Baran L, Filip M. Activation of serotonin (5-HT)1A receptors inhibits amphetamine sensitization in mice. Life Sci. 2000;66:1011-1019. (Pubitemid 30090391)
19. Ago Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology. 2006;51:914-922. (Pubitemid 44376402)
20. Ago Y, Nakamura S, Baba A, Matsuda T. Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice. J Pharmacol Sci. 2008;106:15-21.
21. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A, et al. Postsynaptic 5-hydroxy- tryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol. 2000;129:1028-1034. (Pubitemid 30142918)
22. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711. (Pubitemid 35335888)